(Q37970447)

26 August 2017

Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management (English)

1 reference

26 August 2017

0 references

0 references

1 reference

Elisabetta Degasperi

2

0 references

Alessio Aghemo

object named as

Alessio Aghemo

3

0 references

Pietro Lampertico

object named as

Pietro Lampertico

4

0 references

author name string

Mauro Viganò

1

1 reference

PubMed ID

22188392

26 August 2017

Massimo Colombo

5

1 reference

PubMed ID

22188392

26 August 2017

language of work or name

English

0 references

publication date

22 December 2011

1 reference

Expert Opinion on Biological Therapy

26 August 2017

1 reference

26 August 2017

12

1 reference

26 August 2017

2

1 reference

26 August 2017

193-207

1 reference

New drugs for rheumatoid arthritis

26 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Statements from the Taormina expert meeting on occult hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Chronic hepatitis B: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Prophylaxis and treatment of hepatitis B in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Hepatitis B and C virus infection in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Infliximab-induced hepatitis: absence of cross-toxicity with etanercept.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Long-term anti-TNFalpha therapy for ankylosing spondylitis in two patients with chronic HBV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Anti-TNF-alpha therapy for rheumatoid arthritis among patients with chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Hepatitis B virus resistance to antiviral drugs: where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

The global burden of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Genetic variation in the interleukin -28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Interferon in the treatment of chronic hepatitis C: a drug caught between past and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Effect of tumour necrosis factor antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Etanercept therapy in two patients with psoriasis and concomitant hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Etanercept treatment in a hemodialysis patient with severe cyclosporine-resistant psoriasis and hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Safety of etanercept therapy in a patient with psoriasis, Down's syndrome and concomitant hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Efficiency and safety of etanercept after acute hepatitis induced by infliximab for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Serious liver disease induced by infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-α) use for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Occult hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646986

10.1517/14712598.2012.646986

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22188392